Outlook Therapeutics, Inc. (OTLK) Form 10-Q Quarterly Reports
Outlook Therapeutics, Inc. (OTLK) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: OTLK
CIK: 1649989
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 09/30
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
KPMG LLP
Auditor SinceSince 9/30/2017 12:00:00 AM
Lead Engagement PartnerGretchen Pinto
Audit LocationPhiladelphia, Pennsylvania, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| SCHEDULE 13G | 2026-10-13 | — | SCHEDULE 13G Filing | 0000919574-26-006871 | View SEC Doc Filr Page |
| 8-K | 2026-09-30 | 2026-09-25 | FORM 8-K | 0001104659-26-112356 | View SEC Doc Filr Page |
| 8-K | 2026-09-18 | 2026-09-16 | FORM 8-K | 0001104659-26-108952 | View SEC Doc Filr Page |
| 4 | 2026-09-02 | 2026-09-01 | 4 Filing | 0002074701-26-000005 | View SEC Doc Filr Page |
| 3 | 2026-09-02 | 2026-09-01 | 3 Filing | 0002074701-26-000003 | View SEC Doc Filr Page |
| 8-K | 2026-08-27 | 2026-08-23 | FORM 8-K | 0001104659-26-102446 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-19 | — | SCHEDULE 13G Filing | 0001649553-26-000111 | View SEC Doc Filr Page |
| 10-Q | 2026-08-18 | 2026-06-30 | 10-Q | 0001104659-26-098415 | View SEC Doc Filr Page |
| NT 10-Q | 2026-08-17 | 2026-06-30 | NT 10-Q | 0001104659-26-097838 | View SEC Doc Filr Page |
| 4 | 2026-08-14 | 2026-08-14 | OWNERSHIP DOCUMENT | 0001104659-26-097406 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-08-14 | — | SCHEDULE 13D/A Filing | 0000899140-26-000895 | View SEC Doc Filr Page |
| 4 | 2026-08-14 | 2026-08-12 | FORM 4 | 0000899140-26-000894 | View SEC Doc Filr Page |
| 4 | 2026-08-14 | 2026-08-14 | PRIMARY DOCUMENT | 0001649989-26-000009 | View SEC Doc Filr Page |
| 8-K | 2026-08-14 | 2026-08-12 | FORM 8-K | 0001104659-26-096510 | View SEC Doc Filr Page |
| 424B5 | 2026-08-14 | — | 424B5 | 0001104659-26-096504 | View SEC Doc Filr Page |
| 8-K | 2026-08-14 | 2026-08-14 | FORM 8-K | 0001104659-26-096478 | View SEC Doc Filr Page |
| 424B5 | 2026-08-12 | — | 424B5 | 0001104659-26-094970 | View SEC Doc Filr Page |
| 8-K | 2026-08-12 | 2026-08-12 | FORM 8-K | 0001104659-26-094848 | View SEC Doc Filr Page |
| 4 | 2026-07-29 | 2026-07-29 | PRIMARY DOCUMENT | 0001649989-26-000008 | View SEC Doc Filr Page |
| 8-K | 2026-07-24 | 2026-07-24 | FORM 8-K | 0001104659-26-086685 | View SEC Doc Filr Page |
| 8-K | 2026-07-24 | 2026-07-21 | FORM 8-K | 0001104659-26-086406 | View SEC Doc Filr Page |
| 4 | 2026-07-23 | 2026-07-21 | PRIMARY DOCUMENT | 0001649989-26-000007 | View SEC Doc Filr Page |
| 4 | 2026-07-23 | 2026-07-21 | PRIMARY DOCUMENT | 0001649989-26-000006 | View SEC Doc Filr Page |
| EFFECT | 2026-07-21 | — | EFFECT Filing | 9999999995-26-002376 | View SEC Doc Filr Page |
| 424B3 | 2026-07-21 | — | 424B3 | 0001104659-26-085430 | View SEC Doc Filr Page |